期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

奥卡西平治疗小儿癫87例 被引量：3

下载PDF
导出
摘要 目的评估奥卡西平治疗小儿癫的临床疗效、安全性及药物保留率。方法采用开放性自身对照随访研究方法,对2008年6月～2010年9月经小儿癫门诊诊治的87例各种类型癫患儿给予奥卡西平治疗,从开始处方用药到随访时间1～2年。其中单药治疗56例,添加治疗31例。通过逐步加量的方法达到目标剂量。奥卡西平起始剂量5～10 mg.kg-1.d-1,最初1～2个月每周递增,以20～40 mg.kg-1.d-1为目标剂量,分2次口服。结果总有效率81.61%(71例),完全控制率66.67%(58例)。单药治疗总有效率87.50%(49例),完全控制率76.79%(43例);添加治疗总有效率70.97%(22例),完全控制率48.39%(15例)。单药治疗和添加治疗总有效率差异无统计学意义(χ2=3.63,P>0.05)。不良反应发生率5.62%,未见严重不良反应。1年药物保留率76.40%。结论奥卡西平治疗小儿癫安全、有效,药物保留率高,有较好的依从性和耐受性。
作者 尹艳秋 蔡婧 闫丹丹 袁雪涛 印芳颖
机构地区 吉林大学中日联谊医院儿科
出处 《医药导报》 CAS 北大核心 2012年第5期603-605,共3页 Herald of Medicine
关键词 奥卡西平 癫 小儿 不良反应 药物保留率
分类号 R971.6 [医药卫生—药品] R720.5 [医药卫生—儿科]
  • 相关文献

参考文献13

  • 1BEGHI E,BERG A,CARPIO A,et al.Comment on epile-ptic seizures and epilepsy:definitions proposed by theInternational League Against Epilepsy(ILAE)and theInternational Bureau for Epilepsy(IBE)[J].Epilepsia,2005,46(10):1698-1702.
  • 2GLAUSER T,BEN-MENACHEM E,BOURGEOIS B,et al.ILAE treatment guidelines:evidence-based analysis ofantiepileptic drug efficacy and effectiveness as initialmonotherapy for epileptic seizures and syndromes[J].Epilepsia,2006,47(7):1094-1120.
  • 3WHELESS J W,CLARKE D F,ARZIMANOGLOU A,et al.Treatment of pediatric epilepsy:European expert opinion,2007[J].Epileptic Disord,2007,9(4):353-412.
  • 4陈倩,李尔珍,罗桂芳,许克铭.奥卡西平治疗儿童癫的疗效及药物不良反应[J].实用儿科临床杂志,2009,24(1):53-55. 被引量：18
  • 5KOTHARE S V,KHURANA D S,MOSTOFI N,et al.Oxca-rbazepine monotherapy in children and adolescents:a single-center clinical experience[J].Pediatr Neurol,2006,35(4):235-239.
  • 6SCHMIDT D,SACHDEO R.Oxcarbazepine for treatment ofpartial epilepsy:a review and recommendations for clinicaluse[J].Epilepsy Behav,2000,1(6):396-405.
  • 7SERDAROGLU G,KURUL S,TUTUNCUOGLU S,et al.Oxcarbazepine the treatment of childhood epilepsy[J].Pedlatr Neurol,2003,28(1):37-41.
  • 8PAULETTO G,BERGONZI P.Oxcarbazepine reduces seiz-ure frequency in a high proportion of patients with both newly diagnosed and refractory partial seizures in clinical practice[J].Seizure,2006,15(3):150-155.
  • 9LIN C H,LU C H,WANG F J,et al.Risk factors of oxca-rbazepine-induced hyponatremia in patients with epilepsy[J].Clin Neuropharmacol,2010,33(6):293-296.
  • 10DONATI F,GOBBI G,CAMPISTOL J,et al.The cognitive effects of oxcarbazepine versus carbamazepine or valproate in newly diagnosed children with partial seizures[J].Seizure,2007,16(5):670-679.

二级参考文献13

  • 1Raju GP,Sarco DP, Poduri A. Oxcarbazepine in children with nocturnal frontal - lobe epilepsy[J]. Pediatr Neurol, 2007,37 ( 5 ) :345 - 349.
  • 2Schdeo R, Beydaun A, Schachter S, et al. Oxcarbazepine (Trileptal) as monotherapy in patients with partial seizures [ J ]. Neurology, 2001,57 (5) :864 -871.
  • 3Coppola G,Franzoni E,Verrotti A,et al. Levetiracetam or oxearbazepine as monotherapy in newly diagnosed benign epilepsy of childhood with centrotemporal spikes ( BECTS ) : An open - label, parallel group trial [J]. Brain Dev,2007,29(5 ) :281 - 284.
  • 4Glauser TA, Nigro M, Sachdeo R, et al. Adjunctive therapy with oxcarbazepine in children with partial seizures. The Oxcarbazepine Pediatric Study Group[ J]. Neurology,2000,54(12) :2237 -2244.
  • 5Bares G, Walkcr EB, Elger CE,et al. Oxcarbazepine placebo -controlled, dose - ranging trial in refractory partial epilepsy [ J ]. Epilepsia, 2000,41 (12) :1597 - 1607.
  • 6Tutor - Crespo M J, Hermida J, Tutor JC. Relation of blood platelet count during carbamazepine and oxcarbazepine treatment with daily dose, and serum concentrations of carbamazepine, carbamazepine - 10,11 - epoxide, and 10 - hydroxycarbazepine [ J]. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub ,2007,151 (1) :91 -94.
  • 7Pauletto G, Bergonzi P, Triveneto Epilepsy Study Group. Oxcarbazepine reduces seizure frequency in a high proportion of patients with both newly diagnosed and refractory partial seizures in clinical practice [ J ]. Seizure,2006,15 ( 3 ) : 150 - 155.
  • 8Bourgeois BF,D'Souza J. Long term safty and toleradility of oxcarbazepine in children:A rewiew of clinical experience [J]. Epilepsy Behav, 2005,7 ( 3 ) :375 - 382.
  • 9Aldenkamp AP, De Krom M, Reijs R. Newer antiepileptic drugs and cognitive issues [ J ]. Epilepsia, 2003,44 : 21 - 29.
  • 10Donati F, Gobbi G, Campistol J. The cognitive effects of oxcarbazepine versus carbamazepine or valproate in newly diagnosed children with partial seizures [J]. Seizure,2007,16 ( 8 ) :670 - 679.

共引文献17

同被引文献20

  • 1THEODOR W M, ELISABETH K M, BERNHARD R. Clin- ical pharmacokinetics of oxcarbazepine [ J ]. Clin Pharmacokinet ,2003,42 ( 12 ) : 1023-1042.
  • 2FLESCH G. Overview of the clinical pharmacokinetics of ox- carbazepine [ J ]. Clin Drug Invest, 2004,24 (4) : 185 -203.
  • 3BRING P, ENSOM M H. Does oxcarbazepine warrant thera- peutic drug monitoring: a critical review [ J ]. Clin Pharm, 2008,47 (12) :767-778.
  • 4JOHANNESSEN S, BATTINO D, BERRY D, et al. Therape- utic drug monitoring of the newer antiepileptic drugs [ J ]. Ther Drug Monit,2003,25 (3) :347-363.
  • 5NEELS H M, SIERENS A C, NAELAERTS K, et al. Thera- peutic drug monitoring of old and newer anti-epileptic drugs [Jl. Clin Chem Lab Med,2004,42( 11 ) :1228-1255.
  • 6BOUQUIE R, DAILLY E, BENTUE-FERRER D. Therapeutic drug monitoring of oxcarbazepine [ J ]. Therapie, 2010,65 ( 1 ) :61-65.
  • 7Theodor W May, Elisabeth Korn Merker, Bernhard Ra-mbeck. Clinical Pharmaeokinetics of Oxcarbaz- epine[J]. Clin Pharmcokinet, 2003, 42 ( 12 ): 1023- 1042.
  • 8Kothare SV, Khurana DS, Mosmfi N, et al. Oxcarbaz- epine monotherapy in children and adolescents:a sin- gle-center clinical experience [J].Pediatr Neurol, 2006,35 (4) :235-239.
  • 9Flesch G. Overview of the clinical pharmacokinetics of oxcarbazepine[J]. Clin Drug Investig, 2004,24 (4) : 185-203.
  • 10Bring P, Ensom MH. Does oxcarbazepine warrant the rapeutic drug monitoring A critical review[J]. Clin Pharmacokinet, 2008,47 ( 12 ) : 767-778.

引证文献3

二级引证文献12

医药导报
2012年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部